TIDES Insights: Spotlight on TIDES USA Scientific & Strategic Highlights

Keynotes highlight how oligonucleotide manufacturing has evolved from small-scale innovation to industrialised production. Speakers focus on lessons learned in scale-up, quality control, process robustness, and CMC strategy, as well as how manufacturers are preparing for increased clinical and commercial demand.

Insights from personalized CRISPR and RNAi keynotes show how advances in chemistry, delivery, and sequence design are enabling greater specificity and durability. These sessions explore how individualised therapies are being translated from concept to clinic, including regulatory and operational considerations.

Several keynote spotlights focus on overcoming historical delivery barriers through novel ligands, nanotechnology, and cell-selective targeting strategies. These approaches aim to enhance tissue specificity, reduce off-target effects, and unlock new disease areas for oligonucleotide and RNA-based medicines.

Keynotes on RNAi chemistry and precision peptides demonstrate how molecular and chemical optimisation is enabling therapies for challenging indications, including neurological and metabolic diseases. These talks highlight the role of chemistry in improving stability, bioavailability, and therapeutic index.

Across the keynote spotlights, common themes emerge: convergence of modalities, increasing focus on manufacturability early in development, precision targeting, and sustainable production. Together, these insights reflect how the industry is moving from experimental innovation toward scalable, patient-ready therapies.